Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. [electronic resource]
Producer: 20161013Description: 107-21 p. digitalISSN:- 1557-3265
- Anilides -- pharmacology
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Bone Neoplasms -- diagnosis
- Cell Line, Tumor
- Clinical Trials, Phase II as Topic
- Disease Models, Animal
- Drug Resistance, Neoplasm
- Gene Knockdown Techniques
- Humans
- Male
- Mice
- Multicenter Studies as Topic
- Neoplasm Staging
- Phosphorylation
- Positron-Emission Tomography
- Prostatic Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-met -- antagonists & inhibitors
- Pyridines -- pharmacology
- Receptor, Fibroblast Growth Factor, Type 1 -- metabolism
- Signal Transduction -- drug effects
- Treatment Outcome
- Tumor Burden -- drug effects
- Vascular Endothelial Growth Factor Receptor-2 -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.